1. Home
  2. IMNN
  3. IMNN News

Latest Imunon Inc. (IMNN) News on November 25, 2025

IMNN: R&D Day Highlights Potential for IMNN-001…
IMNN

Zacks Small Cap Research

8 days ago

IMNN: R&D Day Highlights Potential for IMNN-001…

Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and ...
IMNN

GuruFocus.com

12 days ago

Imunon Inc (IMNN) Q3 2025 Earnings Call Highlights: Promising Advances in Immunotherapy and ...

Imunon (IMNN) Q3 2025 Earnings Call Transcript
IMNN

Motley Fool

12 days ago

Imunon (IMNN) Q3 2025 Earnings Call Transcript

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
IMNN

GlobeNewswire

12 days ago

IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
IMNN

GlobeNewswire

15 days ago

IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
IMNN

GlobeNewswire

15 days ago

IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
IMNN

GlobeNewswire

18 days ago

IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
IMNN

GlobeNewswire

19 days ago

IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
IMNN

GlobeNewswire

21 days ago

IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer

IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
IMNN

GlobeNewswire

a month ago

IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
IMNN

GlobeNewswire

a month ago

IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting

DNA Cancer Vaccine Clinical Trials & Market Opportunity Outlook 2026 | First Commercial Approval of DNA Cancer Vaccine Anticipated by 2030
IMNN

GlobeNewswire

a month ago

DNA Cancer Vaccine Clinical Trials & Market Opportunity Outlook 2026 | First Commercial Approval of DNA Cancer Vaccine Anticipated by 2030

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
IMNN

GlobeNewswire

a month ago

IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
IMNN

GlobeNewswire

a month ago

IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
IMNN

GlobeNewswire

2 months ago

IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research

IMNN

Zacks Small Cap Research

5 months ago

OTC Markets Hosts Virtual Investor Presentation with Stacy Lindborg, President, CEO, and Board Director of Imunon, and David Bautz, PhD, Senior Analyst at Zacks SCR

IMNN: Translational Data from OVATION 2 Presented…
IMNN

Zacks Small Cap Research

5 months ago

IMNN: Translational Data from OVATION 2 Presented…

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
IMNN

GlobeNewswire

5 months ago

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
IMNN

GlobeNewswire

5 months ago

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™

Life Sciences Investor Forum: Now Available for Online Viewing
IMNN

GlobeNewswire

5 months ago

Life Sciences Investor Forum: Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for June 11th-12th
IMNN

GlobeNewswire

5 months ago

Life Sciences Investor Forum Agenda Announced for June 11th-12th

IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th
IMNN

GlobeNewswire

6 months ago

IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th

ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer
IMNN

Clinical Trials Arena

6 months ago

ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
IMNN

GlobeNewswire

6 months ago

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
IMNN

GlobeNewswire

6 months ago

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS

IMNN: Momentum Continues with Presentations at ASCO and ESMO Gynaecological Cancers…
IMNN

Zacks Small Cap Research

6 months ago

IMNN: Momentum Continues with Presentations at ASCO and ESMO Gynaecological Cancers…

Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More
IMNN

Insider Monkey

6 months ago

Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More

IMNN

MT Newswires

6 months ago

Imunon Closes Private Placement of Shares, Warrants to Raise Up to $9.75 Million

IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
IMNN

GlobeNewswire

6 months ago

IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Imunon announces up to $9.75M private placement priced at-the-market
IMNN

TipRanks

6 months ago

Imunon announces up to $9.75M private placement priced at-the-market

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
IMNN

GlobeNewswire

6 months ago

IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
IMNN

GlobeNewswire

6 months ago

IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules

IMNN

MT Newswires

6 months ago

Sector Update: Health Care Stocks Decline Late Afternoon

IMNN

MT Newswires

6 months ago

Sector Update: Health Care Stocks Softer Friday Afternoon

IMNN

MT Newswires

6 months ago

Top Midday Gainers

IMNN

MT Newswires

6 months ago

Imunon Reports Prolonged Survival in Study of Potential Ovarian Cancer Treatment; Shares Soar Pre-Bell

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
IMNN

GlobeNewswire

6 months ago

IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer

IMUNON Announces Withdrawal of Form S-1 Registration Statement
IMNN

GlobeNewswire

6 months ago

IMUNON Announces Withdrawal of Form S-1 Registration Statement

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19
IMNN

GlobeNewswire

6 months ago

IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19

IMNN: First Site Activated for Phase 3 OVATION 3 Trial…
IMNN

Zacks Small Cap Research

6 months ago

IMNN: First Site Activated for Phase 3 OVATION 3 Trial…

Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
IMNN

GuruFocus.com

6 months ago

Imunon Inc (IMNN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

IMNN

Thomson Reuters StreetEvents

6 months ago

Q1 2025 Imunon Inc Earnings Call

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update
IMNN

GlobeNewswire

6 months ago

IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
IMNN

GlobeNewswire

7 months ago

IMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology
IMNN

GlobeNewswire

7 months ago

IMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025
IMNN

GlobeNewswire

7 months ago

IMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting
IMNN

GlobeNewswire

7 months ago

IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…
IMNN

Zacks Small Cap Research

8 months ago

IMNN: Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer…

FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment
IMNN

Clinical Trials Arena

8 months ago

FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
IMNN

GlobeNewswire

8 months ago

IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

IMNN

Zacks Small Cap Research

9 months ago

IMNN: Phase 3 Ovarian Cancer Trial to get Underway in Mar 2025…

IMNN

Thomson Reuters StreetEvents

9 months ago

Q4 2024 Imunon Inc Earnings Call

Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges
IMNN

GuruFocus.com

9 months ago

Imunon Inc (IMNN) Q4 2024 Earnings Call Highlights: Promising Advances Amid Financial Challenges

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study
IMNN

GlobeNewswire

9 months ago

IMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study

Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial
IMNN

Clinical Trials Arena

9 months ago

Imunon reports immunogenicity and safety data from DNA plasmid vaccine trial

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
IMNN

GlobeNewswire

9 months ago

IMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
IMNN

GlobeNewswire

9 months ago

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
IMNN

GlobeNewswire

9 months ago

IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer

IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
IMNN

GlobeNewswire

9 months ago

IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer

IMNN

Zacks Small Cap Research

10 months ago

IMNN: Gearing Up to Initiate Phase 3 Ovarian Cancer Trial in 1Q25…

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
IMNN

GlobeNewswire

a year ago

IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
IMNN

GlobeNewswire

a year ago

IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001

IMNN

Zacks Small Cap Research

a year ago

IMNN: Comes to Alignment with FDA Regarding Phase 3 Protocol for IMNN-001…

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
IMNN

GlobeNewswire

a year ago

IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer

IMNN

Zacks Small Cap Research

a year ago

IMNN: Meeting with FDA in Preparation for Phase 3 Ovarian Cancer Trial

Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ...
IMNN

GuruFocus.com

a year ago

Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ...

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
IMNN

GlobeNewswire

a year ago

IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
IMNN

GlobeNewswire

a year ago

IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
IMNN

GlobeNewswire

a year ago

IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
IMNN

GlobeNewswire

a year ago

IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting

Imunon reports inducement grant under NASDAQ listing rule
IMNN

TipRanks

a year ago

Imunon reports inducement grant under NASDAQ listing rule

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
IMNN

GlobeNewswire

a year ago

IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
IMNN

GlobeNewswire

a year ago

UPDATE - IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
IMNN

GlobeNewswire

a year ago

IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

IMNN

MT Newswires

a year ago

Imunon Files for Stock Resale by Security Holders

IMUNON to Host R&D Day on September 18th
IMNN

GlobeNewswire

a year ago

IMUNON to Host R&D Day on September 18th

IMNN: Positive Results for OVATION 2 Trial Supports Advancing IMNN-001 Into Phase 3 Study…
IMNN

Zacks Small Cap Research

a year ago

IMNN: Positive Results for OVATION 2 Trial Supports Advancing IMNN-001 Into Phase 3 Study…

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
IMNN

GlobeNewswire

a year ago

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
IMNN

GlobeNewswire

a year ago

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

IMNN

MT Newswires

a year ago

Top Midday Decliners

Imunon’s shares soar after IL-12 therapy success in Phase II trial
IMNN

Pharmaceutical Technology

a year ago

Imunon’s shares soar after IL-12 therapy success in Phase II trial

IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
IMNN

GlobeNewswire

a year ago

IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

IMNN

MT Newswires

a year ago

Sector Update: Health Care Stocks Edge Higher Late Afternoon

IMNN

MT Newswires

a year ago

Sector Update: Health Care

IMNN

MT Newswires

a year ago

Top Midday Gainers

IMNN

MT Newswires

a year ago

Imunon Says Phase 2 Trial Data of Ovarian Cancer Treatment Showed Increase in Overall Survival; Shares Jump

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
IMNN

GlobeNewswire

a year ago

IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
IMNN

GlobeNewswire

a year ago

IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
IMNN

GlobeNewswire

a year ago

IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
IMNN

Business Wire

a year ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
IMNN

GlobeNewswire

a year ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23
IMNN

GlobeNewswire

a year ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
IMNN

Simply Wall St.

a year ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May
IMNN

Reuters

a year ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
IMNN

AFP

a year ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Enduring role of 'treasuring the past' hailed
IMNN

PR Newswire

a year ago

Enduring role of 'treasuring the past' hailed

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
IMNN

GlobeNewswire

a year ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Italian energy company targets Britain for fleet of 20 mini-nukes
IMNN

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend
IMNN

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?
IMNN

Simply Wall St.

a year ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Share on Social Networks: